Shanti Overseas (India) Ltd
SHANTIShanti Overseas (India) Ltd is cheap for a reason. The P/E sits at the 3rd percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: the P/E sits at the 3rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (34 weeks in) while the P/E sits at the 3rd percentile of its own 9-year range. Underneath, the last four quarters read deteriorating, and 503% of the last 3 years' profit arrived as cash. What settles it: whether the quarters turn before the discount closes.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Shanti Overseas (India) Ltd trades at ₹5.2, in a downtrend and 34 weeks into that stage. That is −46.7% against its own 200-day average. It sits at 0% of a 52-week range of ₹5 to ₹23. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (17 weeks and counting).
Today the stock is in a downtrend — week 34 of stage 4, confirmed. At ₹5.2 it trades −46.7% versus its 200-day average and sits at 0% of its 52-week range (₹5–₹23).
Against the market, two honest reads. Cumulative: over the last 8.6 years the stock moved −82% while the NIFTY 500 moved +142% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (17 weeks and counting; last ahead the week of 2025-11-28) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Shanti Overseas (India) Ltd trades at 3.0× P/E, near the bottom of its own range — cheaper only 3% of the time. Its long-run median P/E is 3.9×, measured across 8.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 3.0× is near the bottom of its own range — cheaper only 3% of the time, against a long-run median of 3.9× measured over 8.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
At its price on 13 June 2026, Shanti Overseas (India) Ltd was priced for profit growth of about −12.7% a year. The market pays that at 3.0× P/E, the 3rd percentile of its own 9-year range.
What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is the whole of what a buyer is backing. Both readings sit on the same earnings, so they are one reading rather than two.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements. Every other number on this page is read off the live quote.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Shanti Overseas (India) Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 9 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +123.6% | −51.0% | −31.6% | −10.3% |
| Share price | −65.3% | −29.2% | −26.1% | — |
4-Factor Sector Score
32.3/100 — rank 34 of 49 in Trading · 56% evidence confidence
Shanti Overseas (India) Ltd scores 32.3 out of 100 against the 49 companies it is compared with in Trading, ranking 34. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 11.2 + 4.6 + 13.2 + 3.3 = 32.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Shanti Overseas (India) Ltd reported ₹1.0 Cr of revenue in the Dec 25 quarter, −94.2% year on year. Over 10 years it has compounded at −10.3% a year. The last full year, FY25, came in at ₹23.8 Cr. The last four reported quarters add to ₹8.6 Cr.
FY25 revenue came in at ₹23.8 Cr (+123.6% on the year), capping 10 years at −10.3% compound. The latest quarter (Dec 25) printed ₹1.0 Cr, −94.2% year on year.
Pace check: the last four quarters averaged −2.3% growth against the decade's −10.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −63.4% over the last 4 quarters against −22.6%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Shanti Overseas (India) Ltd's operating margin is −216.5% in the Dec 25 quarter, −200.5 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −18.8% to 10.2%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is −216.5%, −200.5 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −18.8%–10.2%.
🚨 Why the margin moved: operating margin went −200.5 pp year on year while gross margin went +15.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Shanti Overseas (India) Ltd earned ₹1.6 Cr of net profit in the Dec 25 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY25 year was a loss of ₹2.8 Cr. That is 157.3% of the quarter's revenue.
Dec 25 profit was ₹1.6 Cr, null year on year. On the full year, FY25 printed ₹−2.8 Cr (null).
🚨 Read this profit with care: at ₹1.6 Cr it is larger than the whole quarter's revenue of ₹1.0 Cr — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −216.5% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 503% of Shanti Overseas (India) Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹−2.2 Cr of operating cash against ₹−2.8 Cr of profit. After ₹0.0 Cr of capital spending, ₹−2.0 Cr was left as free cash.
FY25: operating cash of ₹−2.2 Cr against reported profit of ₹−2.8 Cr, leaving free cash of ₹−2.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 503% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 503%: the cash cycle tightened 23 days between FY20 and FY25 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Shanti Overseas (India) Ltd's cash conversion cycle runs 37 days in FY25, down from 60 days in FY20. Capital spending ran ₹−22.0 Cr over the last 3 years. At FY25 sales of ₹23.8 Cr each day of that cycle holds about ₹0.1 Cr, so roughly ₹2.0 Cr sits inside the business at any moment.
FY25: debtors at 37 days, inventory at 0 days — roughly 0.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 37 days, tighter than FY20's 60.
The full loop: cash goes out to suppliers and production on day 0; stock waits 0 days to sell; customers pay about 37 days after that; and suppliers themselves are paid at 4 days — netting out to the 37-day cycle.
In money terms: at FY25 sales of ₹23.8 Cr, each day of the cycle holds about ₹0.1 Cr — so the 37-day loop keeps roughly ₹2.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−22.0 Cr over the last 3 fiscal years against ₹4.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Shanti Overseas (India) Ltd earns a ROCE of −25% in FY25. That is up from a trough of −30% in FY23. Return on invested capital clears the cost of that capital by −25.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −11.7% net margin on 1.18× asset turns.
FY25 ROCE is −25%, recovered from a FY23 trough of −30% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): −11.7% net margin × 1.18× asset turns × 1.75× balance-sheet leverage ≈ −24.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: −13.1% − 12.0% = a −25.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Shanti Overseas (India) Ltd carries ₹1.3 Cr of borrowings against ₹11.5 Cr of equity in FY25, a debt-to-equity of 0.12. Operating profit covers the interest bill −75×. Over 5 years borrowings went from ₹41.1 Cr to ₹1.3 Cr. Capital spending ran ₹−22.0 Cr across the last 3 of those years.
FY25: borrowings of ₹1.3 Cr against equity of ₹11.5 Cr — a debt-to-equity of 0.12. Operating profit covers the interest bill −75×. Over 5 years borrowings went from ₹41.1 Cr to ₹1.3 Cr while capital spending ran ₹−22.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 52.1 points of Shanti Overseas (India) Ltd over 8 quarters, the biggest move on the register. That takes promoters to 0.0% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −52.1 points over 8 quarters to 0.0%. Note the structure: promoters hold under 20% — this is a widely-held company where institutions, not a family, set the direction.
🚨 Why the register moved: promoters drove it (−52.1 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Shanti Overseas (India) Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 74.2/100Favorable setup69% evidence | 28.8/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.6/20 P/E 19.8× · PEG — 15% evidence | 16.5/20 RS sector 67.7% · RS bench 94.8% · 1Y 61.3%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 28.8 + 18.3 + 10.6 + 16.5 = 74.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Rashi Peripherals LtdRPTECH | 68.7/100Favorable setup75% evidence | LEADER | 24.5/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 16.8% · OPM 3% 76% evidence | 10.7/20 P/E 17.4× · PEG — 15% evidence | 18.8/20 RS sector 57.1% · RS bench 82.2% · 1Y 197.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 14.7 + 10.7 + 18.8 = 68.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Magnus Steel & Infra Ltd517320 | 67.1/100Thin evidence · provisional56% evidence | 27.6/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.1% · 1Y —4 of 5 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.6 + 18.5 + 9.2 + 11.8 = 67.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Nupur Recyclers LtdNRL | 67.0/100Favorable setup87% evidence | BREAKING OUT | 22.2/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.5/20 P/E 47.1× · PEG — 50% evidence | 18.7/20 RS sector 43.1% · RS bench 70.4% · 1Y 66.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.6 + 9.5 + 18.7 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 63.1/100Mixed-positive evidence63% evidence | FADING | 25.3/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.4/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 25.3 + 17.4 + 10.4 + 10 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Mangalam Global Enterprise LtdMGEL | 61.0/100Mixed-positive evidence80% evidence | 25.3/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 16.1/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 8.5/20 RS sector -18.9% · RS bench -0.2% · 1Y -9.8%10 of 11 weeks ahead 100% evidence | |
| Exact sum: 25.3 + 16.1 + 11.1 + 8.5 = 61 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tembo Global Industries LtdTEMBO | 59.9/100Mixed-positive evidence80% evidence | TURNING | 21.8/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 11× · PEG — 15% evidence | 8.3/20 RS sector -17.6% · RS bench -0.1% · 1Y 27.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 18.5 + 11.3 + 8.3 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Euro Pratik Sales LtdEUROPRATIK | 59.7/100Mixed-positive evidence73% evidence | BREAKING OUT | 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.1/20 P/E 34.1× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 10 weeks ahead 0% evidence |
| Exact sum: 15.1 + 19.5 + 15.1 + 10 = 59.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9Ivalue Infosolutions LtdIVALUE | 59.6/100Mixed-positive evidence60% evidence | BREAKING OUT | 20.3/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.4/25 ROCE 25.4% · OPM 10% 95% evidence | 10.9/20 P/E 14.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.3 + 18.4 + 10.9 + 10 = 59.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Vision Infra Equipment Solutions LtdVIESL | 58.7/100Thin evidence · provisional56% evidence | FADING | 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 11.2/20 P/E 11.6× · PEG — 15% evidence | 8.7/20 RS sector -2.5% · RS bench 15.7% · 1Y 93%10 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 11.2 + 8.7 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Arisinfra Solutions LtdARIS | 57.8/100Mixed-positive evidence65% evidence | BASING | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.3/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 16.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench 1.5% · 1Y -7.4%3 of 10 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15.3 + 10.8 + 10 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Patel Retail LtdPATELRMART | 52.8/100Mixed-positive evidence60% evidence | FADING | 17.7/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.5/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -16.2%5 of 10 weeks ahead 0% evidence |
| Exact sum: 17.7 + 14.5 + 10.6 + 10 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Sudarshan Pharma Industries LtdSUDARSHAN | 51.1/100Mixed-positive evidence76% evidence | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 11.3/20 P/E 35.6× · PEG — 50% evidence | 5.6/20 RS sector -23.8% · RS bench -7% · 1Y -15.7%2 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.5 + 13.7 + 11.3 + 5.6 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Fabtech Technologies LtdFABTECH | 50.8/100Thin evidence · provisional52% evidence | ASLEEP | 17.4/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.4 + 12.4 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 50.5/100Mixed-positive evidence75% evidence | FADING | 17.9/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.3/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 102× · PEG — 15% evidence | 12.2/20 RS sector -3.6% · RS bench 15.7% · 1Y -0.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 11.3 + 9.1 + 12.2 = 50.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16BMW Ventures LtdBMW | 50.0/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.9 + 12 + 11.1 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Yogi LtdYOGI | 49.6/100Thin evidence · provisional58% evidence | 20.2/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.0/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.6/20 P/E 53.7× · PEG — 15% evidence | 9.8/20 RS sector -7% · RS bench 10.4% · 1Y -8.4%2 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.2 + 10 + 9.6 + 9.8 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18SG Mart LtdSGMART | 48.9/100Mixed-negative evidence90% evidence | LEADER | 14.1/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 95% evidence | 8.9/25 ROCE 10.2% · OPM 4.5% 95% evidence | 8.3/20 P/E 74.6× · PEG 1.92 65% evidence | 17.6/20 RS sector 31.8% · RS bench 54.6% · 1Y 125.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.9 + 8.3 + 17.6 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 54.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Shiv Aum Steels LtdSHIVAUM | 47.2/100Thin evidence · provisional55% evidence | TURNING | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.6/20 P/E 64.1× · PEG — 50% evidence | 11.4/20 RS sector — · RS bench 34.1% · 1Y —2 of 2 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 7.6 + 11.4 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Adani Enterprises LtdADANIENT | 45.2/100Mixed-negative evidence93% evidence | LEADER | 14.5/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.5/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 173× · PEG 1.96 65% evidence | 14.5/20 RS sector 2.3% · RS bench 22% · 1Y 43.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 8.5 + 7.7 + 14.5 = 45.2 · Decision use: Price leads the evidence: RS versus the benchmark is 22%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21MMTC LtdMMTC | 45.0/100Mixed-negative evidence96% evidence | ASLEEP | 14.8/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 8.1/25 ROCE 8.7% · OPM — 84% evidence | 14.0/20 P/E 48× · PEG 0.92 100% evidence | 8.1/20 RS sector -18.2% · RS bench -1.3% · 1Y 1.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 8.1 + 14 + 8.1 = 45 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22State Trading Corporation of India LtdSTCINDIA | 42.8/100Thin evidence · provisional54% evidence | ASLEEP | 18.8/35 Revenue — · PAT 100% · OPM change -14.6 pp 43% evidence | 7.4/25 ROCE -0.9% · OPM — 60% evidence | 11.5/20 P/E 15.7× · PEG — 50% evidence | 5.1/20 RS sector -29.2% · RS bench -5.4% · 1Y -0.9%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.8 + 7.4 + 11.5 + 5.1 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Riddhi Siddhi Gluco Biols Ltd524480 | 42.4/100Mixed-negative evidence82% evidence | TURNING | 12.8/35 Revenue 74.8% · PAT 0% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.6/20 P/E 38.6× · PEG — 50% evidence | 16.5/20 RS sector 8.6% · RS bench 29% · 1Y 42.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.5 + 6.6 + 16.5 = 42.4 · Decision use: Price leads the evidence: RS versus the benchmark is 29%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24RRP Semiconductor LtdRRP | 41.7/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.5/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 64.7% · RS bench 6.5% · 1Y 142.7%0 of 1 week ahead 70% evidence | |
| Exact sum: 11.4 + 5.5 + 10 + 14.8 = 41.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Cropster Agro Ltd523105 | 40.5/100Mixed-negative evidence65% evidence | 15.9/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.3/20 P/E 31× · PEG — 15% evidence | 3.0/20 RS sector -72.9% · RS bench -62.7% · 1Y -70.2%0 of 4 weeks ahead 70% evidence | |
| Exact sum: 15.9 + 11.3 + 10.3 + 3 = 40.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Dhunseri Ventures LtdDVL | 40.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.7/25 ROCE 6.7% · OPM 39% 95% evidence | 9.2/20 P/E 4.9× · PEG — 50% evidence | 8.8/20 RS sector -21.7% · RS bench -4.2% · 1Y -22.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.7 + 9.2 + 8.8 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Hardwyn India LtdHARDWYN | 39.7/100Mixed-negative evidence87% evidence | ASLEEP | 13.7/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.4/25 ROCE 4.8% · OPM 13% 95% evidence | 11.7/20 P/E 62.6× · PEG — 50% evidence | 1.9/20 RS sector -28.8% · RS bench -15.6% · 1Y 23.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 12.4 + 11.7 + 1.9 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Blue Pearl Agriventures LtdBPAGRI | 39.5/100Mixed-negative evidence69% evidence | 20.3/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.2/20 RS sector -33.9% · RS bench -25.1% · 1Y -48.7%1 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 20.3 + 6.3 + 8.7 + 4.2 = 39.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29PTC India LtdPTC | 39.4/100Mixed-negative evidence82% evidence | ASLEEP | 13.4/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 10.6/20 P/E 9.3× · PEG — 50% evidence | 2.7/20 RS sector -24.1% · RS bench -8.7% · 1Y -7.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 12.7 + 10.6 + 2.7 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hexa Tradex LtdHEXATRADEX | 38.8/100Mixed-negative evidence65% evidence | ASLEEP | 16.9/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.7/20 RS sector -23.2% · RS bench -6.9% · 1Y -12.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 6.2 + 10 + 5.7 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Neueon Corporation LtdNEUEON | 38.0/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.8/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.1/20 RS sector 12.7% · RS bench 44.5% · 1Y —5 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.8 + 10 + 15.1 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Kothari Industrial Corporation LtdKOTIC | 33.8/100Adverse evidence63% evidence | ASLEEP | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -58.8% · RS bench -47.8% · 1Y -68.7%0 of 7 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.6 + 10 + 3.5 = 33.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33BN Agrochem LtdBNAGROCHEM | 32.8/100Adverse evidence77% evidence | ASLEEP | 12.7/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.1/20 P/E 140× · PEG — 15% evidence | 6.6/20 RS sector -17.1% · RS bench -23.3% · 1Y -22.5%6 of 8 weeks ahead 70% evidence |
| Exact sum: 12.7 + 4.4 + 9.1 + 6.6 = 32.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34Shanti Overseas (India) Ltdthis pageSHANTI | 32.3/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.6/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.2/20 P/E 3× · PEG — 50% evidence | 3.3/20 RS sector -60.6% · RS bench -49.7% · 1Y -51.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.6 + 13.2 + 3.3 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Uniphos Enterprises LtdUNIENTER | 30.1/100Adverse evidence69% evidence | ASLEEP | 12.4/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.6/25 ROCE 0.8% · OPM — 80% evidence | 9.0/20 P/E 32.7× · PEG — 50% evidence | 4.1/20 RS sector -43.9% · RS bench -24.1% · 1Y -38%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 4.6 + 9 + 4.1 = 30.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Oswal Agro Mills LtdOSWALAGRO | 24.3/100Adverse evidence67% evidence | ASLEEP | 2.7/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.8/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -50.6% · RS bench -32% · 1Y -50.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 2.7 + 7.8 + 10 + 3.8 = 24.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Bizotic Commercial LtdBIZOTIC | 64.9/100Thin evidence · provisional45% evidence | 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.7/20 P/E 48.7× · PEG — 15% evidence | 16.8/20 RS sector 89.2% · RS bench 102% · 1Y 262%10 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 19.8 + 18.6 + 9.7 + 16.8 = 64.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38Proventus Agrocom LtdPROV | 57.0/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.5/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.3/20 P/E 45.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 39.7% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.5 + 13.3 + 11.6 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.6/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 74.6% · 1Y 176.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12 = 56.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40SK Minerals & Additives Ltd544584 | 55.9/100Thin evidence · provisional36% evidence | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 18.9/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.4/20 P/E 25.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.6 + 18.9 + 10.4 + 10 = 55.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Aayush Art and Bullion LtdAAYUSHBULL | 55.4/100Thin evidence · provisional48% evidence | 21.1/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.2/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 243× · PEG — 15% evidence | 12.2/20 RS sector 0.1% · RS bench 18.5% · 1Y 20.6%10 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 21.1 + 13.2 + 8.9 + 12.2 = 55.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -11.2%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 248× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 96.2% · 1Y — 25% evidence | |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.3 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Pramara Promotions LtdPRAMARA | 51.9/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 14.1/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.3/20 RS sector 5.7% · RS bench 29% · 1Y 58.3%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 14.1 + 6.9 + 14.3 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Manbro Industries Ltd512595 | 51.3/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.9/20 RS sector -17.3% · RS bench 37.2% · 1Y 40.1%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.9 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Satani Bearings LtdSATANIBRG | 46.0/100Thin evidence · provisional38% evidence | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.5/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5055× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 116.9% · 1Y 189.8%10 of 10 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.5 + 4.5 + 8.6 + 12.4 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Le Merite Exports LtdLEMERITE | 45.9/100Thin evidence · provisional46% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 8.6/20 RS sector -12.1% · RS bench 15% · 1Y 45.9%2 of 12 weeks ahead to 2026-05-17 100% evidence | |
| Exact sum: 18.9 + 9.1 + 9.3 + 8.6 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Keto Motors Ltd537392 | 43.1/100Thin evidence · provisional38% evidence | 16.1/35 Revenue — · PAT -41.7% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 6428× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 341.9% · 1Y — 25% evidence | |
| Exact sum: 16.1 + 6 + 8.5 + 12.5 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49A-1 LtdA1L | 40.8/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.8/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.0/20 RS sector -24.9% · RS bench -16% · 1Y 25.3%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 10.8 + 8.8 + 5 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Shanti Overseas (India) Ltd's share price today?
Shanti Overseas (India) Ltd trades at ₹5.2, −65.3% over the past year. The company is valued at ₹5.8 Cr. The stock sits at the very bottom of its 52-week range (₹5–₹23), −46.7% versus its 200-day average. On the tape, the price is in a downtrend, 34 weeks in. — as of 14 August 2026.
What were Shanti Overseas (India) Ltd's latest quarterly results?
Shanti Overseas (India) Ltd reported revenue of ₹1.0 Cr and net profit of ₹1.6 Cr for the Dec 25 quarter. Earnings per share were ₹1.46. The operating margin was −216.5%, 200.5 pp lower than a year earlier. — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's revenue?
Shanti Overseas (India) Ltd reported revenue of ₹1.0 Cr in the Dec 25 quarter, −94.2% year on year. For the full FY25 fiscal year, revenue was ₹23.8 Cr (+123.6%). Over the last 10 years revenue compounded at −10.3% a year. — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's profit?
Shanti Overseas (India) Ltd earned ₹1.6 Cr of net profit in the Dec 25 quarter. Full-year FY25 profit was ₹−2.8 Cr. The operating margin ran −216.5% in the latest quarter. — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's market cap?
Shanti Overseas (India) Ltd's market capitalisation is ₹5.8 Cr at a share price of ₹5.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's P/E ratio?
Shanti Overseas (India) Ltd trades at a P/E of 3.0×, at the 3rd percentile of its own 9-year range, against a long-run median of 3.9×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does Shanti Overseas (India) Ltd pay a dividend?
Not in its latest year — Shanti Overseas (India) Ltd's dividend payout was 0% of profit in FY25. It did record a payout in 1 of its last 12 reported fiscal years, so there is a history but no current dividend. — as of 14 August 2026.
Is Shanti Overseas (India) Ltd overvalued?
On its own history, Shanti Overseas (India) Ltd looks cheap: its P/E of 3.0× has been cheaper only 3% of the time in 9 years (long-run median 3.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 14 August 2026.
How is Shanti Overseas (India) Ltd performing?
Shanti Overseas (India) Ltd is in a downtrend, 34 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 17 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is Shanti Overseas (India) Ltd in an uptrend?
No — the price is in a downtrend (week 34 of stage 4), trading −46.7% versus its 200-day average and at the very bottom of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is Shanti Overseas (India) Ltd beating the market?
Not lately — on a trailing-13-week view Shanti Overseas (India) Ltd is currently behind the NIFTY 500 (17 weeks and counting; last ahead the week of 2025-11-28), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.6 years the stock moved −82% against the NIFTY 500's +142% — behind the index over the full window. — as of 14 August 2026.
Will Shanti Overseas (India) Ltd's share price go up?
This page publishes no price forecast for Shanti Overseas (India) Ltd. What it measures instead: the share price is ₹5.2, the price is in a downtrend 34 weeks in. Its P/E of 3.0× sits at the 3rd percentile of its own 9-year range. — as of 14 August 2026.
Who owns Shanti Overseas (India) Ltd?
Promoters hold 0.0% of Shanti Overseas (India) Ltd, foreign institutions null%, domestic institutions null% and the public 100.0% (latest quarter). The biggest move on the register over the last two years: Promoters cut 52.1 points over 8 quarters. — as of 14 August 2026.
Does Shanti Overseas (India) Ltd have too much debt?
No — Shanti Overseas (India) Ltd's debt-to-equity is 0.12, and operating profit covers the interest bill −75×. FY25 borrowings were ₹1.3 Cr against equity of ₹11.5 Cr. The returns on this page are earned, not borrowed — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's capex?
Shanti Overseas (India) Ltd spent ₹−22.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is Shanti Overseas (India) Ltd's cash flow?
Shanti Overseas (India) Ltd consumed ₹2.2 Cr of operating cash in FY25 — cash flowed out rather than in (free cash flow: ₹−2.0 Cr). Reported profit that year was ₹−2.8 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is Shanti Overseas (India) Ltd's profit real cash?
Yes — over the last 3 fiscal years, 503% of Shanti Overseas (India) Ltd's reported profit arrived as operating cash. Though the latest year ran at 79% — the trend is the thing to watch. In FY25, operating cash was ₹−2.2 Cr against reported profit of ₹−2.8 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 14 August 2026.
Where is Shanti Overseas (India) Ltd in its business cycle?
Shanti Overseas (India) Ltd's FY25 operating margin was −18.8%, against a 12-year band of −18.8%–10.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran −216.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What growth does Shanti Overseas (India) Ltd's price assume?
At its price on 13 June 2026, Shanti Overseas (India) Ltd was priced for profit growth of about −12.7% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 14 August 2026.
What could break the Shanti Overseas (India) Ltd story?
The sharpest disagreement: the P/E sits at the 3rd percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is Shanti Overseas (India) Ltd a stock worth studying right now?
This is not investment advice. The machine read: Shanti Overseas (India) Ltd is cheap for a reason. The P/E sits at the 3rd percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the quarters turn before the discount closes. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.